Fig. 1From: Soluble CD73 as biomarker in patients with metastatic melanoma patients treated with nivolumabThe activity of CD73 in hydrolysing AMP was inhibited in presence of the CD73 inhibitor APCP (40–100 µM). APCP was added to the samples before adding the substrate AMP. Data are mean ± S.E.MBack to article page